CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies

Haematologica. 2019 Feb;104(2):226-235. doi: 10.3324/haematol.2018.197152. Epub 2019 Jan 10.

Abstract

Primary cutaneous CD30-positive T-cell lymphoproliferative disorders are the second most common subgroup of cutaneous T-cell lymphomas. They include two clinically different entities with some overlapping features and borderline cases: lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. Molecular studies of primary cutaneous anaplastic large cell lymphoma reveal an increasing level of heterogeneity that is associated with histological and immunophenotypic features of the cases and their response to specific therapies. Here, we review the most significant genetic, epigenetic and molecular alterations described to date in primary cutaneous CD30-positive T-cell lymphoproliferative disorders, and their potential as therapeutic targets.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biomarkers, Tumor*
  • Clonal Evolution / genetics
  • Diagnosis, Differential
  • Disease Susceptibility
  • Gene Rearrangement
  • Humans
  • Immunophenotyping
  • Ki-1 Antigen / genetics
  • Ki-1 Antigen / metabolism*
  • Lymphoma, T-Cell, Cutaneous / diagnosis*
  • Lymphoma, T-Cell, Cutaneous / etiology*
  • Lymphoma, T-Cell, Cutaneous / therapy
  • Lymphoproliferative Disorders / diagnosis*
  • Lymphoproliferative Disorders / etiology*
  • Lymphoproliferative Disorders / therapy
  • Molecular Targeted Therapy
  • Phenotype
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • Ki-1 Antigen